References
- Reginster J, Minne H W, Sorensen O H, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83–91
- Harris S T, Watts N B, Genant H K, et al. Effect of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344–1352
- Miller P D, Brown J P, Siris E S, Hoseyni M S, Axelrod D W, Bekker P J. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 1999; 106: 513–520
- Delmas P D, Garnero P. Utility of biochemical markers of bone turnover in osteoporosis. Osteoporosis, R Marcus, D Feldman, J Kelsey. Academic Press, San Diego 1996; 1075–1088
- Taguchi Y, Gorai I, Zhang M G, Chaki O, Nakayama M, Minaguchi H. Differences in bone resorption in menopause in Japanese women with normal and low bone mineral density. Quantitation of urinary cross-linked N-Telopeptides. Calcif Tissue Int 1998; 62: 395–399
- Garnero P, Delmas P D. New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996; 59(Suppl 1)2–9
- Hannon R A. Comparison of measurement of urinary CrossLaps by Osteosal™- a rapid point-of-care Test and by ELISA. Bone 1998; 23(Suppl)630
- Eastell R, Barton I, Hannon R A, Chines A, Garnero P, Delmas P D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18: 1051–1056
- Brown J P, Kendler D L, McClung M R, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103–111
- Hosking D, Adami S, Felsenberg D, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomized, placebo-controlled study. Curr Med Res Opin 2003; 19: 383–394
- Taggart H, Bolognese M A, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002; 77: 262–270
- Adachi J D, Adami S, Miller P D, et al. Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) 2001; 13: 347–354